GSCs were cultured in a selective medium for NSC, composed of DMEM F-12 and Neurobasal 1:1, B-27 supplement without vitamin A (Life Technologies Italia, Milan, Italy), 2 mM L-glutamine (Euroclone S.p.A., Milan, Italy), 10 ng/mL recombinant human bFGF and 20 ng/mL recombinant human EGF (Miltenyi Biotec, Bergish Gladbach, Germany), 20 UI/mL penicillin and 20 µg/mL streptomycin (Euroclone S.p.A., Milan, Italy). After isolation, the medium was replaced every 3 days to remove stroma and red blood cells residues, catabolic products and to supply fresh nutrients. Debris and adherent death cells generally were eliminated after a couple of passages. The isolated cells propagate in culture as free-floating spheres defined as tumorspheres [6 (link)], which appeared in 15–20 days of culture after isolation. When tumorspheres reached an average size of 100 μm in diameter, the culture was ready to be passed and expanded. At each passage (P), tumorspheres were mechanically dissociated using a sterilized p200 pipette set at 180–200 µL and pipetting up and down 100–150 times to achieve a single-cell suspension.
Recombinant human egf
Manufactured by Miltenyi Biotec
Sourced in Germany, Canada
Recombinant human EGF is a protein that functions as a growth factor. It is produced using recombinant DNA technology.
Automatically generated - may contain errors
Lab products found in correlation
Recombinant human bfgf, by Miltenyi Biotec (7 mentions)
Penicillin, by Euroclone (6 mentions)
Streptomycin, by Euroclone (6 mentions)
Laminin, by Thermo Fisher Scientific (5 mentions)
B 27 supplement without vitamin a, by Thermo Fisher Scientific (5 mentions)
L glutamine, by Euroclone (3 mentions)
Dmem f12, by Euroclone (2 mentions)
Neurobasal 1 1, by Thermo Fisher Scientific (2 mentions)
Neurobasal 1, by Thermo Fisher Scientific (2 mentions)
Dmem f12, by Thermo Fisher Scientific (2 mentions)
Neurocult ns a proliferation medium, by STEMCELL (1 mentions)
Celigo s imaging cytometer, by Revvity (1 mentions)
Heparin, by STEMCELL (1 mentions)
Valproic acid, by Merck Group (1 mentions)
Temozolomide, by Merck Group (1 mentions)
7 protocols using recombinant human egf
1
Isolation and Expansion of Glioblastoma Stem Cells
2
SRH Sphere Formation Assay Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
SRH single cell suspensions that were generated by trypsin-EDTA dissociation were prepared for sphere formation assays. The cells were seeded in NeuroCult™ NS-A Proliferation Medium (Stemcell Technologies, Vancouver, BC, Canada), supplemented with 20 ng/mL recombinant human EGF (Miltenyi Biotech Bergisch Gladbach, Germany), 10 ng/mL recombinant human bFGF (Miltenyi Biotech Bergisch Gladbach, Germany), and 2 µg/mL heparin (Stemcell Technologies, Vancouver, BC, Canada) at a density of 10–1000 cells/well in Nunclon Sphera™ ultra-low attachment flat bottom 96-well plates (Thermo Fisher Scientific, Waltham, MA, USA). SRH spheres were cultured at 37 °C in humidified air containing 5% CO2 for seven days before being scored with the Celigo® S Imaging Cytometer (Nexcelom Bioscience, Lawrence, MA, USA). The sphere forming efficiency (%) was calculated as the number of tumor spheres divided by number of cells seeded × 100.
3
Glioma Stem Cell Lines Expansion
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All the glioma stem cell (GSC) lines used in this work (GBM2, GBM7, G144, G179, G166, GliNS2, GBM04) were isolated from patients affected by glioblastoma and extensively characterized for their stemness properties. GBM2, GBM7, G144, G166, GliNS2, GBM04 derived from classic glioblastoma multiforme, while G179 derived from a giant cell variant glioblastoma. All the GSC lines have been already expanded in vitro as stable cell lines and used as powerful model for studying their biology and testing drug susceptibility [26 (link), 27 (link)]; furthermore their cytogenomic and epigenomic profiles were well characterized [28 (link)].
The stemness properties of these GSC lines were periodically monitored, as already described [29 (link)]. Cell expansion was carried out in a proliferation permissive medium composed by DMEM F-12 (Euroclone) and Neurobasal 1:1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine (Euroclone), 10 ng/ml recombinant human bFGF and 20 ng/ml recombinant human EGF (Miltenyi Biotec), 20 UI/ml penicillin and 20 μg/ml streptomycin (Euroclone) (complete medium). GSCs were cultured in adherent culture condition in T-25 cm3 flasks coated with 10 μg/ml laminin (Invitrogen), in 5% CO2/95% O2 atmosphere.
The stemness properties of these GSC lines were periodically monitored, as already described [29 (link)]. Cell expansion was carried out in a proliferation permissive medium composed by DMEM F-12 (Euroclone) and Neurobasal 1:1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine (Euroclone), 10 ng/ml recombinant human bFGF and 20 ng/ml recombinant human EGF (Miltenyi Biotec), 20 UI/ml penicillin and 20 μg/ml streptomycin (Euroclone) (complete medium). GSCs were cultured in adherent culture condition in T-25 cm3 flasks coated with 10 μg/ml laminin (Invitrogen), in 5% CO2/95% O2 atmosphere.
4
Characterization of Glioblastoma Stem Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All the GSC lines used in this work (GBM2, G144, G179, G166, GliNS2, and GBM04) were isolated from patients affected by GBM and extensively characterized for their stem cell properties. GBM2, GBM7, G144, G166, GliNS2, and GBM04 derived from classic glioblastoma multiforme, while G179 derived from a giant cell variant glioblastoma. All the GSC lines have been already expanded in vitro as stable cell lines and used as powerful model for studying their biology and testing drug susceptibility [18 (link), 19 (link)]. In 2013, our research group characterized their cytogenomic and epigenomic profiles [20 (link)]. The stemness properties of the GSC lines were periodically monitored, as already described in Baronchelli et al. 2013 [20 (link)]. Cell expansion was carried out in a proliferation permissive medium composed by DMEM F-12 (Euroclone) and Neurobasal 1 : 1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine (Euroclone), 10 ng/mL recombinant human bFGF and 20 ng/mL recombinant human EGF (Miltenyi Biotec), and 20 UI/mL penicillin and 20 μg/mL streptomycin (Euroclone) (complete medium). GSCs were cultured in adherent culture condition in T-25 cm2 flasks coated with 10 μg/mL laminin (Invitrogen), in 5% CO2/95% O2 atmosphere.
5
Glioblastoma Stem Cell Culture Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The six GSC lines used in this work (GBM2, GBM7, G144, G166, G179 and GliNS2) have been isolated from patients affected by GBM [20] (link), [45] (link) and in 2013, our research group characterized their cytogenomic and epigenomic profiles [2] (link). The stemness properties of the GSC lines were periodically monitored, as already described [2] (link). Cells were cultured in adherent culture condition using 10 μg/ml laminin (Invitrogen) in a proliferation permissive medium composed by DMEM F-12 and Neurobasal 1:1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine, 10 ng/ml recombinant human bFGF and 20 ng/ml recombinant human EGF (Miltenyi Biotec), 20UI/ml penicillin and 20 μg/ml streptomycin (Euroclone) (complete medium).
6
Glioblastoma Stem Cell Characterization
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The GSC lines (GBM2, G144, G166, GBM04) were isolated from patients affected by glioblastoma and characterized for their stemness properties from a genetic and molecular point of view (Baronchelli et al., 2013 (link)). All the GSC lines were already expanded in vitro as stable cell lines and used as powerful model for studying their biology and testing drug susceptibility, furthermore their cytogenomic and epigenomic profiles were well characterized (Riva et al., 2014 (link), 2018 (link); Cilibrasi et al., 2017 (link)). GSC were cultured in adherent culture condition using 10 mg/ml laminin (Invitrogen) in a proliferation permissive medium composed by DMEM F-12 and Neurobasal 1:1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine, 10 ng/ml recombinant human bFGF and 20 ng/ml recombinant human EGF (Miltenyi Biotec), 20 UI/ml penicillin and 20 g/ml streptomycin (Euroclone; complete medium).
7
Glioblastoma Stem Cell Culture and Drug Treatments
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cell lines and cell culture conditions. The seven GSC lines used in this study (GBM2, GBM7, GBM04, G144, G166, G179 and GliNS2) were isolated from patients affected by GBM (22, 23) and, in 2013, our research group characterized their cytogenomic and epigenomic profiles (24) . Cells were cultured in neural stem cell-specific medium, and their stem-like properties were periodically monitored, as previously described (22) (23) (24) . Cells were cultured in an adherent culture condition using 10 µg/ml laminin (Invitrogen) in a proliferation permissive medium composed of Dulbecco's modified Eagle's medium (DMEM)/F-12 and Neurobasal 1:1 (Invitrogen), B-27 supplement without vitamin A (Invitrogen), 2 mM L-glutamine, 10 ng/ml recombinant human bFGF and 20 ng/ml recombinant human EGF (Miltenyi Biotec), 20 uI/ ml penicillin and 20 µg/ml streptomycin (Euroclone).
Drug treatments. Valproic acid (sodium salt; Sigma) was dissolved in sterile water to a stock concentration of 0.5 M. Temozolomide (Sigma) was dissolved in sterile DMSO at the final concentration of 0.05 M. All drugs were stored at -20˚C.
In vitro treatments were performed using 2 mM VPA for 24, 48,72, 96 h and 14 and 30 days; with regard to TMZ, we administered 50, 100, 200 or 400 µM TMZ for 48 or 72 h.
Drug treatments. Valproic acid (sodium salt; Sigma) was dissolved in sterile water to a stock concentration of 0.5 M. Temozolomide (Sigma) was dissolved in sterile DMSO at the final concentration of 0.05 M. All drugs were stored at -20˚C.
In vitro treatments were performed using 2 mM VPA for 24, 48,72, 96 h and 14 and 30 days; with regard to TMZ, we administered 50, 100, 200 or 400 µM TMZ for 48 or 72 h.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!